PILOT AND FEASIBILITY PROGRAM ? RESEARCH STRATEGY The Pilot and Feasibility Program of the Mayo Translational PKD Center (MTPC) is designed to attract new investigators to PKD research. These investigators can be of three different types: (a) PIs with no past or current NIH funding, (b) established PIs with NIH funding but which have not worked in PKD, and (c) PKD- established investigators (rare) with new or innovative ideas or approaches. The P&F Program goal is to provide sufficient funds to generate obtain preliminary data to support applications for research grants from external agencies, especially R and K awards from NIH. Applications submitted in response to the biannual RFA, use a R03-NIH format and are processed through a two-phase review. Phase 1 is the initial PKD- relatedness screening followed by review and ranking of the internal Scientific Review Committee. In Phase 2, the PIs (of top 6-8 ranked proposals) present their work to the External Advisory Committee (EAC) at the annual retreat. The EAC makes the final ranking and recommendation for the 4-funded P&F grants (two pilots from MTPC funds and two pilots from Mayo Clinic cost-share funds). The metrics for success of the P&F program are (a) abstracts and meeting presentations, (b) peer-reviewed publications and (c) external funding. For the initial period of MTPC funding, the Pilot and Feasibility Program enjoyed success by these metrics. From a pool of 37 received proposals, the P&F program funded 11 investigators: 5 new investigators, 5 non- PKD established investigators and one PKD-investigator (new approach, cycle 3). Funding for the 8 pilots completed resulted in 13 peer-reviewed papers, 10 other abstracts and two meeting, oral presentations. These pilot-PIs also submitted 14 national grants resulting in 5 external and two internal grants funded. Together, the P&F program, the selection process and the success-metrics, help to sustain and expand the Center Membership. The current renewal will allow the MTPC Center to expand as well as enrich the already successful Pilot and Feasibility program.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK090728-10
Application #
9764355
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
10
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Ata, Hirotaka; Ekstrom, Thomas L; Martínez-Gálvez, Gabriel et al. (2018) Robust activation of microhomology-mediated end joining for precision gene editing applications. PLoS Genet 14:e1007652
Chebib, Fouad T; Perrone, Ronald D; Chapman, Arlene B et al. (2018) A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. J Am Soc Nephrol 29:2458-2470
Yu, Alan S L; Shen, Chengli; Landsittel, Douglas P et al. (2018) Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. Kidney Int 93:691-699
Masyuk, Tatyana V; Masyuk, Anatoliy I; LaRusso, Nicholas F (2018) Polycystic liver disease: The interplay of genes causative for hepatic and renal cystogenesis. Hepatology 67:2462-2464
Cornec-Le Gall, Emilie; Olson, Rory J; Besse, Whitney et al. (2018) Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease. Am J Hum Genet 102:832-844
He, Kai; Ma, Xiaoyu; Xu, Tao et al. (2018) Axoneme polyglutamylation regulated by Joubert syndrome protein ARL13B controls ciliary targeting of signaling molecules. Nat Commun 9:3310
Idowu, Jessica; Home, Trisha; Patel, Nisha et al. (2018) Aberrant Regulation of Notch3 Signaling Pathway in Polycystic Kidney Disease. Sci Rep 8:3340
Nowak, Kristen L; You, Zhiying; Gitomer, Berenice et al. (2018) Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol 29:571-578
Brosnahan, Godela M; Abebe, Kaleab Z; Moore, Charity G et al. (2018) Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials. Am J Kidney Dis 71:666-676
Besse, Whitney; Choi, Jungmin; Ahram, Dina et al. (2018) A noncoding variant in GANAB explains isolated polycystic liver disease (PCLD) in a large family. Hum Mutat 39:378-382

Showing the most recent 10 out of 192 publications